Nanobody against ela2a to treat inflammatory bowel diseases (ibd) or irritable bowel syndrome (ibs)

The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) including Gluten hypersensitivity. The inventors showed that ELA2A secreted by epithelial cells in the extracellular space is over-expressed in IBD conditions degrading tight junction proteins and controlling cytokines expression. Overexpression of ELA2A conferred a pro-inflammatory phenotype both in cell expression systems and in vivo in animal model of IBD. The inventors also showed that ELA2 over-expressing intestinal epithelial cells increase the release of CXCL8 protein compared to control cells. The increased CXCL-8 protein release observed in cells overexpressing ELA2A is inhibited by ELAFIN addition to the culture, in a dose-dependent manner. In particular, the invention relates to inhibitors of Elastase ELA2A, for use in the treatment of Inflammatory Bowel Diseases, such as Crohn's Disease, Ulcerative Colitis, Celiac disease, and Pouchitis.

Keywords: Inflammatory Bowel Diseases, ELA2A
Patent Application number: PCT/EP2017/064786
Inventors:
Corinne ROLLANDCéline DERAISON-MANUELNathalie VERGNOLLE

You might also be interested in

Contact

Inserm Transfert

Research tool licensing team

researchtools@inserm-transfert.fr